Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Byoung Chul Cho

Showing results (11-20 of 452) with videos related to

Pageof 46
Sort By:
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 20, 2014
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancerHelmout Modjtahedi, Byoung Chul Cho, Martin C Michel, et al.
JTO Clinical and Research Reports|February 1, 2024
Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With <i>HER2</i> Mutation: A Case ReportSangho Nam, Sun Min Lim, Byoung Chul Cho, et al.
Therapeutic Advances in Medical Oncology|March 11, 2015
Nivolumab in NSCLC: latest evidence and clinical potentialRaghav Sundar, Byoung-Chul Cho, Julie R Brahmer, et al.
Lung Cancer (Amsterdam, Netherlands)|March 16, 2013
Personalized therapy on the horizon for squamous cell carcinoma of the lungHan Sang Kim, Tetsuya Mitsudomi, Ross A Soo, et al.
Yonsei Medical Journal|December 22, 2011
Elevated serum C-reactive protein as a prognostic marker in small cell lung cancerSoojung Hong, Young Ae Kang, Byoung Chul Cho, et al.
Yonsei Medical Journal|January 5, 2010
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancerByoung Chul Cho, Joo Hang Kim, Ross A Soo, et al.
Cancer Treatment Reviews|February 26, 2018
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategiesSun Min Lim, Nicholas L Syn, Byoung Chul Cho, et al.
Cancer Discovery|January 13, 2022
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLCSun Min Lim, Chang Gon Kim, Jii Bum Lee, et al.
Analytical Biochemistry|May 4, 2011
Multiple target loci assembly sequencing (mTAS)Hyojun Han, Jung-Ki Yoon, Byoung Chul Cho, et al.
Therapeutic Advances in Medical Oncology|December 22, 2022
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancerJiyun Lee, Zofia Piotrowska, Ross Soo, et al.
Pageof 46

Showing results (11-20 of 452) with videos related to

Sort By:
Pageof 46
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 20, 2014
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancerHelmout Modjtahedi, Byoung Chul Cho, Martin C Michel, et al.
JTO Clinical and Research Reports|February 1, 2024
Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With <i>HER2</i> Mutation: A Case ReportSangho Nam, Sun Min Lim, Byoung Chul Cho, et al.
Therapeutic Advances in Medical Oncology|March 11, 2015
Nivolumab in NSCLC: latest evidence and clinical potentialRaghav Sundar, Byoung-Chul Cho, Julie R Brahmer, et al.
Lung Cancer (Amsterdam, Netherlands)|March 16, 2013
Personalized therapy on the horizon for squamous cell carcinoma of the lungHan Sang Kim, Tetsuya Mitsudomi, Ross A Soo, et al.
Yonsei Medical Journal|December 22, 2011
Elevated serum C-reactive protein as a prognostic marker in small cell lung cancerSoojung Hong, Young Ae Kang, Byoung Chul Cho, et al.
Yonsei Medical Journal|January 5, 2010
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancerByoung Chul Cho, Joo Hang Kim, Ross A Soo, et al.
Cancer Treatment Reviews|February 26, 2018
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategiesSun Min Lim, Nicholas L Syn, Byoung Chul Cho, et al.
Cancer Discovery|January 13, 2022
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLCSun Min Lim, Chang Gon Kim, Jii Bum Lee, et al.
Analytical Biochemistry|May 4, 2011
Multiple target loci assembly sequencing (mTAS)Hyojun Han, Jung-Ki Yoon, Byoung Chul Cho, et al.
Therapeutic Advances in Medical Oncology|December 22, 2022
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancerJiyun Lee, Zofia Piotrowska, Ross Soo, et al.
Pageof 46